OTS - Construction Project of Biomay's Manufacturing Facility Fully on Schedule
2021. May 12. 19:02
Vienna, Austria , 12. May 2021. (APA/OTS) - Construction work on
Biomay's new headquarters and biotech manufacturing facility in
Aspern Seestadt, Vienna, is progressing on schedule. Seven months
after the groundbreaking ceremony in September 2020, the building
shell has now been completed. Ongoing activities are currently
focused on the interior works and the installation of the complex
heat, ventilation and air conditioning (HVAC) and utility systems.
- Cross reference: Picture is available at AP Images
(http://www.apimages.com) -
Dr. Hans Huber, Chief Executive Officer of Biomay said: "We are
delighted and impressed to witness the rapid and timely progress of
our building project. Internal and external engineering teams and
the construction workers are doing an excellent job. It is a
pleasure to see how all the team members are working together
effectively in a concerted effort to meet Biomay's goals in terms
of schedule, quality and budget. Seeing the satisfying progress, we
are highly confident that the remaining half of the project will
stay on track as well."
As for the months to come, the building as such is planned to
be completed in September 2021, followed by the manufacturing
equipment and process utilities to be installed by Q3/2021. Biomay
and its staff will move to the new site at the end of this year.
After commissioning and qualification, the company will start up
manufacturing operations for its clients in Q1/2022.
About the Facility
A number of parallel GMP manufacturing lines will be erected on
a total floor area of about 4000 square meters, increasing Biomay's
capacities by a factor of 10 with respect to batch size and volume
(gross bioreactor scales: 5L, 50L, 150L and 750L). Furthermore, a
dedicated area of the building will allow the production of
innovative, personalized (patient-specific) batches.
About Biomay
Biomay AG is a biopharmaceutical contract development and
manufacturing organization (CDMO) with international reach. In
particular, Biomay is recognized as supplier for plasmid DNA
(pDNA), recombinant proteins and messenger RNA (mRNA). Biomay's
clients include start-ups, midsize biotech companies and
multinational enterprises, predominantly from Europe and the US.
Beside manufacturing of active ingredients and drug products
according to GMP standards, the company offers process and assay
development as well as manufacturing of microbial cell banks.
Contact:
Dr. Christian Gruber / media@biomay.com / +43-7966296-100 /
www.biomay.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.